Nanobody-Derived Bispecific CAR-T Therapy Enhances Anti-Tumor Efficacy of T Cell Lymphoma Treatment

0
205
Investigators demonstrated that nanobody-derived bispecific CAR-T cells significantly improved anti-tumor efficacy in T-lymphoma treatment.
[Molecular Therapy Oncolytics]
AbstractFull ArticleGraphical Abstract